Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.68 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | NAMPT | P43490 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8363734 | 0.98 | PTPN1 (0.74) | PTPN1NPSR1LMNAENPP3ENPP1 | |
| SCHEMBL7863859 | 0.96 | PTPN1 (0.66) | PTPN1NPSR1LMNAENPP3ENPP1 | |
| SCHEMBL7865123 | 0.92 | NAMPT (0.72) | PTPN1NPSR1LMNAENPP3ENPP1 | |
| Hydrochloric Acid SCHEMBL435505 | 0.91 | NAMPT (0.70) | PTPN1NPSR1LMNAENPP3ENPP1 | |
| SCHEMBL28656982 | 0.88 | PTPN1 (0.89) | PTPN1NPSR1LMNAENPP3ENPP1 | |
| SCHEMBL125695 | 0.88 | PTPN1 (0.89) | PTPN1NPSR1LMNAENPP3ENPP1 | |
| SCHEMBL13144615 | 0.84 | ALDH1A1 (0.58) | NPSR1LMNAENPP3ENPP1ENPP2 | |
| SCHEMBL27383392 | 0.84 | ALDH1A1 (0.58) | PTPN1NPSR1LMNAENPP3ENPP1 | |
| SCHEMBL13105759 | 0.84 | PTPN1 (0.74) | PTPN1NPSR1LMNAENPP3ENPP1 | |
| SCHEMBL19302972 | 0.83 | ALDH1A1 (0.69) | KDM4EMAPTALDH1A1CYP2C19NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027295-A1 | FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021057818-A1 | FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| EP-3208263-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VentiRx Pharmaceuticals, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9718796-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027295-A1 | FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | F11, TFPI, F7 | PTPN1 2370/4885NPSR1 2164/4885LMNA 776/4885 |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | TLR8, TLR9, TLR1 | PTPN1 905/4885NPSR1 1485/4885LMNA 1929/4885 |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | PTPN1 3108/4885NPSR1 4696/4885LMNA 4011/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | PTPN1 3108/4885NPSR1 4696/4885LMNA 4011/4885 |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, PDK3, PDK4 | PTPN1 4055/4885NPSR1 4794/4885LMNA 3933/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | PTPN1 3108/4885NPSR1 4696/4885LMNA 4011/4885 |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | PTPN1 3108/4885NPSR1 4696/4885LMNA 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.